Brain Cancer
Peregrine Pharmaceuticals Doses First Patient in Cotara Phase II Brain Cancer Trial In India
Published in Cancer Weekly, August 14th, 2007
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, announced that the first patient has been administered Cotara(R) in a new clinical trial designed to evaluate the safety and efficacy of this novel tumor necrosis therapy being developed for the treatment of glioblastoma multiforme (GBM), a deadly form of brain cancer.
"We are delighted that patient treatment has begun in this important Phase II clinical trial that was designed to further confirm the encouraging signs of anti-tumor activity seen in earlier Cotara brain cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-08-14)
More Articles from Cancer Weekly
- Breast Cancer
Biofield Signs Master License Agreement with the MacKay Group to Distribute, Manufacture, Develop and Commercialize the Biofield Breast Cancer Diagnostic System (BDS) - Breast Cancer
Chicagoland Affiliate of Susan G. Komen for the Cure, State Lawmakers, Breast Cancer Survivors, Faith Leaders Rally for Action on Breast Cancer - Breast Cancer
Hooters Donates $250,000 to the V Foundation for Cancer Research Towards Kelly Jo Dowd Breast Cancer Research Grant - Breast Cancer
National Breast Cancer Foundation Unveils Innovative Web Site for Survivors - Breast Cancer
Power3 Medical Products, Inc. Provides Results from 60 Patient Blinded Validation Study of BC-SeraPro - Breast Cancer
Susan G. Komen for the Cure Announces Chief Financial Officer, Vice President of Health Sciences, Associate General Counsel - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
